Short description
Angion Biomedica is a clinical stage organ restoration biopharmaceutical company focused on renal disease.
Description
Angion Biomedica is a clinical-stage organ restoration biopharmaceutical company focused on renal disease. Its investigational drug BB3 is entering phase 3 for delayed graft function following kidney transplant and phase 2 for acute kidney injury following open-heart surgery using cardiopulmonary bypass.
Last funding
Noaccess
Sign in for full access
Total funding
$$2020202
Sign in for full access
Location
Uniondale, New York, United States, North America
Founded on
January 1, 1998
Closed on
June 1, 2023
Exited on
February 5, 2021
Went public on
February 5, 2021
Stock symbol
ANGN
Non-profit?
No
Acquired?
No
Employees count
101-250
Revenue range
$7890 - 12340
Sign in for full access
Investors
Nopepepe, Cannot Access, Nopepepe, Blurry Noaccess
Sign in for full access
Founders
Itzhak Goldberg
Funding rounds count
1
Portfolio organisations count
Noaccess, Noaccessforu
Sign in for full access
Lead investments count
1
Exits count
Nopepepe, Absolutely Noaccess
Sign in for full access
IPO exits count
1